Indian vaccine maker Bharat Biotech said to consider $500 million IPO – CNBC TV18

Indian vaccine developer Bharat Biotech International Ltd is considering an initial public offering (IPO) that could raise more than $500 million, according to a report by Bloomberg, citing people familiar with the matter.

Deliberations are ongoing and details of the potential share sale, including its size and timing, could change, the people said, asking not to be identified as the information is private. A representative for Bharat Biotech did not immediately respond to a request for comment, as per the report.

Founded in 1996, the Hyderabad-based company says it has delivered more than 9 billion vaccine doses globally. Its portfolio includes vaccines for Covid-19 and hepatitis B, as well as treatments for burns and diarrhoea.

Also read: India to offer free HPV vaccine to 14-Year-old girls in nationwide campaign

India’s market for first-time share sales has seen a subdued start to 2026 following two consecutive years of record fund-raising. Equities have come under pressure amid slowing earnings growth, global trade uncertainty and uneven foreign inflows. Large offerings in the pipeline include those of Jio Platforms Ltd, National Stock Exchange of India Ltd and several property firms.